Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bioject Medical Technologies and ImmunoVaccine Technologies have entered into a collaborative research agreement to assess utilization of the Biojector 2000 for the delivery of ImmunoVaccine's vaccine enhancement platform, DepoVax.
Subscribe to our email newsletter
This research will test the efficacy of an ImmunoVaccine Technologies’s (IVT) pandemic influenza vaccine formulation delivered using Bioject’s flagship Bioject B2000 device.
The research will compare the onset, magnitude and duration of the anti-influenza response using the Bioject B2000 device against the same responses using standard needle-injection procedures.
Richard Stout, executive vice president and chief medical officer of Bioject, said: “Needle-free injection therapy (NFIT) systems provide enhancing technologies for vaccines, and we are confident that IVT’s vaccine preclinical trial will reaffirm the significant benefits of Bioject’s NFIT systems.”